The North American Neuroendocrine Tumor Society (NANETS) recently published a position statement in support of the plan for COVID-19 vaccination for patients with neuroendocrine neoplasms (NENs), including well differentiated neuroendocrine tumors (NETs) and poorly differentiated neuroendocrine carcinomas (NECs). The statement suggests that NEN survivors and patients with NENs on observation or undergoing cancer treatment should be offered COVID-19 vaccination as long as any components of the vaccine are not contraindicated.  If vaccine supplies are limited, patients planning to start treatment, currently receiving treatment for cancer, and those immediately (<6 months) post treatment should be prioritized for COVID-19 vaccination (recognizing additional risk factors such as advanced age, co-morbidities, and other social and demographic factors such as poverty, limited access to healthcare and under-represented minorities also need to be considered). The statement also considers guidelines for specific timing of vaccine administration depending on the undergone treatment.

Read the full announcement here.